NCT05036798 2022-09-07Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.Tianjin Medical University Cancer Institute and HospitalPhase 2 Unknown30 enrolled